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Abstract 
Carbon nanotubes (CNTs) have attracted great interest of the nano community and beyond. 
However, the biomedical applications of CNTs arouse serious concerns for their unknown in 
vivo consequence, in which the information of pharmacokinetics, metabolism and toxicity of 
CNTs is essential. In this review, we summarize the updated data of CNTs from the bio-
medical view. The information shows that surface chemistry is crucial in regulating the in vivo 
behaviors of CNTs. Among the functionalization methods, PEGylation is the most efficient 
one to improve the pharmacokinetics and biocompatibility of CNTs. The guiding effects of the 
pharmacokinetics, metabolism and toxicity information on the biomedical applications of 
CNTs are discussed. 
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Introduction 
Since  the  discovery,  carbon  nanotubes  (CNTs) 
have attracted great interest for their potential appli-
cations in various areas [1]. In biomedical area, CNTs 
have been widely used in bio-analysis, therapeutics, 
drug  delivery  and  early  diagnostics.  These  applica-
tions are booming in recent years [2-4]. For example, 
Moon et al. showed that CNTs could target and de-
struct tumors by photothermal effect in situ [5]. Liu et 
al. reported that CNTs could deliver doxorubicin and 
paclitaxel  to  tumors  to  enhance  the  tumor  growth 
inhibition [6, 7]. The applications of CNTs in Raman 
imaging [8], near infrared (NIR) fluorescence imaging 
[9] and radiological imaging [10] were also reported. 
Moreover, there is a trend to combine the therapeutics 
and early diagnostics (namely theranostics) together 
[11-13]. Such combinations on CNTs have been done 
[2, 14]. 
With  the  rapid  development  of  CNTs  in  bio-
medical area, the safety concern is aroused and stud-
ied among scientists of chemistry, pharmacology and 
toxicology [15, 16]. Our group documented that the 
information on the absorption, distribution, metabo-
lism, excretion/toxicity (ADME/T) of CNTs was in-
dispensible for  the  safety  studies [17]. We unveiled 
that CNTs were easily trapped in reticuloendothelial 
system (RES) and induced slight toxicity to liver and 
lungs  [18-20].  Other  reports  suggested  that  CNTs 
were nontoxic after careful surface modification [21, 
22].  However,  the  guiding  information  for 
theranostics is still limited to date. 
In this review, we summarize the updated data 
of CNTs from the biomedical view with focus on the 
pharmacokinetics, metabolism and toxicity of CNTs in 
vivo. We intend to elucidate the connection between 
the  pharmacological  applications  and  toxicological 
information  of  CNTs.  The  importance  of  surface 
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chemistry in regulating the in vivo behavior of CNTs is 
stressed. 
Pharmacokinetics and biodistribution of 
CNTs 
The  pharmacokinetics  and  biodistribution  of 
CNTs have been studied as long as the safety issue of 
CNTs was proposed [23]. The blood circulation time 
and accumulation of CNTs in animal affect their bio-
medical applications and toxicity. Serving as a drug 
vehicle,  the  long  blood-circulated  CNTs  may  accu-
mulate more in tumor, making them efficient for the 
cancer diagnostics and treatment [24]. To study the 
pharmacokinetics and biodistribution of CNTs, vari-
ous  analytical  techniques  have  been  developed  for 
measuring CNTs in bio-samples [17]. With more in-
formation collected, we might get a chance to know 
how these data guide the biomedical applications of 
CNTs. 
Pristine CNTs are hydrophobic and easy to ag-
gregate. It is difficult to disperse them in biosystems. 
Studying  pristine  CNTs  is  in  the  pure  toxicological 
evaluations  as  well  as  the  professional  risk  assess-
ments.  For  the  biomedical  applications,  CNTs  are 
dispersed  with  the  aid  of  suspending  reagents  or 
chemical functionalization. Here, we only discuss the 
pharmacokinetics  and  biodistribution  of  these  dis-
persible CNTs. 
CNTs, which are simply dispersed with surfac-
tant,  are  easily  cleared  from  blood  circulation  and 
accumulate in RES organs. We studied the biodistri-
bution  of  Tween  80  dispersed  single-walled  CNTs 
(SWCNTs)  in  mice  (Figure  1)  [19].  The  skeleton  of 
SWCNTs was labeled with stable isotope 13C and the 
SWCNT contents in tissues were acquired by meas-
uring  the  13C  abundance.  Tween  80  dispersed 
SWCNTs were fully cleared from blood circulation at 
1  day  post  intravenous  injection.  They  were  easily 
recognized by macrophages and thereby captured by 
RES in liver and spleen. These SWCNTs remained in 
liver and spleen for over 3 months [20]. The less dis-
persed SWCNTs forming larger aggregates were fil-
tered  by  pulmonary  capillary  vessels.  According  to 
the  results  of  13C  abundance  measurements,  CNT 
content in lungs decreased in the first month postex-
posure.  Very  similar  results  were  reported  by 
Cherukuri et al. They dispersed SWCNTs with a sur-
factant  named  Pluronic  F108  and  the  sample  was 
centrifuged  at  100,000  g  for  4  hours  to  remove  the 
aggregated SWCNTs [25]. By measuring the charac-
teristic NIR fluorescence of individual SWCNTs, they 
found that Pluronic F108 dispersed SWCNTs majorly 
accumulated  in  liver,  while  the  pulmonary  uptake 
was  undetectable.  Considering  only  individual 
SWCNTs emit NIR fluorescence, it is unknown from 
this case whether SWCNTs aggregate in vivo or not. 
For  multi-walled  CNTs  (MWCNTs),  similar  results 
were reported. Tween 80 dispersed MWCNTs accu-
mulated in liver and spleen with a short blood circu-
lation time [26]. Serum dispersed MWCNTs accumu-
lated in lungs [27]. In a word, the simply dispersed 
CNTs  are  easily  recognized  by  macrophages  and 
cleared from blood very fast. This characteristic limits 
their application in drug delivery. However, simply 
dispersed CNTs may find their position in diagnostics 
and thermal therapy. Yang et al. reported that CNTs 
could be recognized by lymph cells and migrate along 
lymph  vessels  [28].  Thus,  CNTs  may  be  promising 
materials for sentinel lymph node detection, which is 
crucial in cancer therapy. Moreover, the slow migra-
tion of CNTs makes them ideal for thermal therapy, 
because CNTs injected in tumor would stay for a long 
time.  Under  NIR  irradiation  or  in  radiofrequency 
field,  the  heat  generated by  CNTs  could  kill  tumor 
cells [5, 29]. 
 
Figure 1. Biodistribution of Tween 80 dispersed SWCNTs 
in mice after intravenous injection. Adapted from reference 
[19] with permission. 
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By carefully choosing suspending reagents, the 
pharmacokinetics and biodistribution of CNTs can be 
improved significantly. Dai and coworkers developed 
polyethylene  glycol-phospholipid  (PEG-PL)  dis-
persed  CNTs  for  biomedical  detection,  imaging, 
thermal therapy and drug delivery. PEG is one of the 
most  efficient  reagents  to  improve  the  pharmacoki-
netics behavior of exotic substances by shielding the 
exotic substances from the opsonin recognition [30]. 
PEG  chains  were  linked  to  PL  molecules  to  form  a 
hydrophilic-hydrophobic  structure  [24,  31].  PEG-PL 
suspended  CNTs  undergo  hydrophobic  interaction 
between PL and CNTs. PEG-PL prolonged the blood 
circulation half-life and reduced the RES capture of 
SWCNTs  in  vivo.  Liu  et  al.  reported  that 
PEG2000-PL/SWCNTs  (PEG-PL  dispersed  SWCNTs; 
the molecule weight of PEG: 2000) had a half-life of 
1.2 hours [24]. The half-life could be further prolonged 
by using longer PEG chains and even branched PEG 
chains.  The  circulation  half-life  of 
PEG5000-PL/SWCNTs increased to about 5 hours [31]. 
Using branched PEG chains, the value could be higher 
than  15  hours.  More  recently,  Prencipe  et  al.  used 
γPGA-Py-mPEG  [poly-(γ-glutamic  ac-
id)-pyrine(30%)-poly (ethylene glycol) methyl ethers) 
(70%)] to disperse SWCNTs and studied their blood 
circulation half-life [32]. The dispersion was very sta-
ble and prolonged the circulation half-life of SWCNTs 
to 22.1 hours. Accordingly, the RES capture decreased 
along with the change of PEG-PL molecules. The he-
patic  uptake  of  PEG2000-PL/SWCNTs  was  70%ID/g 
(% injected dose per gram tissue), which decreased to 
40%ID/g for PEG5000-PL/SWCNTs and 30%ID/g for 
br-PEG7000-PL/SWCNTs  (br:  branched).  The  PEG 
density on SWCNTs also regulated the blood circula-
tion, biodistribution and tumor uptake of SWCNTs. 
The  blood  circulation  half-life  increased  along  with 
increasing  the  PEG  density,  while  the  RES  uptake 
decreased  accordingly  [33].  The  good  behaviors  of 
PEG-PL/SWCNTs in vivo make them very useful in 
biomedical areas. PEG-PL/SWCNTs have been used 
to  target  tumors  and  deliver  doxorubicin  and 
paclitaxel  for  cancer  therapy  [6,  7].  They  have  also 
been used for photothermal ablation of tumors [33]. In 
addition, they have been applied in Raman and pho-
toacoustic imaging for diagnostics [10, 34]. 
 
 
Figure 2. Pharmacokinetics of PEG-PL/SWCNTs in mice after intravenous injection. (a) Raman spectra of blood samples after the 
injection of l-PEG2000-PL/SWCNTs (l: linear); (b) Raman spectra of blood samples after the injection of l-PEG5000-PL/SWCNTs; (c) Raman 
spectra of blood samples after the injection of br-PEG7000-PL/SWCNTs; (d) PEG-PL/SWCNTs concentrations in blood at different time 
points postexposure. Adapted from reference [31] with permission. 
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The studies of other nanoparticles suggest that 
covalent PEGylation is more efficient than noncova-
lent PEGylation [30]. This is true for CNTs, too. We 
performed  a  pharmacokinetics  evaluation  of 
PEG-SWCNTs  (covalently  PEGylated  SWCNTs)  in 
mice [35]. After PEG1500 was covalently linked to the 
carboxyl  groups  of  SWCNTs,  the  blood  circulation 
half-life  of  SWCNTs  increased  to  15.3  hours.  Even 
short PEG chains can prolong the circulation half-life 
of CNTs efficiently while using covalent PEGylation. 
Correspondingly,  the  RES  capture  of 
PEG1500-SWCNTs was reduced. The hepatic accumu-
lation level was 19.1 %ID/g for PEG1500-SWCNTs. The 
good  pharmacokinetics  profile  of  PEG-SWCNTs 
makes  them  promising  in  biomedical  applications. 
However,  the  biomedical  applications  of 
PEG-SWCNTs  are  fewer  than  those  of 
PEG-PL/SWCNTs.  
 
 
 
 
 
 
Figure 3. Time-dependent PEG-SWCNT concentrations in blood 
(a) and mice (b) after the intravenous injection to mice. Adapted 
from reference [35] with permission. 
 
There might be two reasons: Firstly, the synthe-
sis of PEG-SWCNTs is much more difficult than that 
of PEG-PL/SWCNTs, which limits the involvement of 
more researchers. Secondly, covalent PEGylation de-
stroys  the  intact  nature  of  SWCNTs,  making  some 
unique  properties  of  SWCNTs  lost.  After  covalent 
PEGylation,  SWCNTs  have  strong  fluorescence, 
which hides the Raman signal of SWCNTs [36]. The 
covalent functionalization also destroys the NIR flu-
orescence signal of SWCNTs. Still, drug delivery sys-
tems  based  on  PEG-CNTs  have  been  developed  at 
cellular level [37, 38] and in vivo level [39]. 
Another  kind  of  functionalized  CNTs  was  de-
veloped  by  Prato  and  coworkers  [40].  CNTs  were 
functionalized  via  cycloaddition  reactions,  where 
functional groups were directly attached to the carbon 
skeleton of CNTs. Singh et al. reported the pharmaco-
kinetics  and  biodistribution  of  amino-CNTs  [41]. 
Amino-CNTs were removed from body very quickly. 
A  small  amount  of  injected  amino-CNTs  were 
trapped in kidneys (20%ID/g), skin (9%ID/g), muscle 
(8.5%ID/g)  and  lungs  (1.3%ID/g).  At  3  hours  post 
injection, only 2%ID of amino-CNTs were detected in 
body.  Another  evaluation  was  performed  by 
McDevitt  et  al.  [42,  43].  They  reported  that  ami-
no-SWCNTs  remained  in  body  for  more  than  24 
hours. At 3 hours postexposure, amino-SWCNTs ac-
cumulated in liver (17.8%ID/g), spleen (14.3%ID/g), 
kidneys (8.3%ID/g) and skin (2.3%ID/g). Except in 
kidneys,  amino-SWCNT  contents  kept  unchanged 
after 24 hours. The different CNT sources and syn-
thesis conditions might attribute to the contradictory 
results of the two groups. Such differences would lead 
to  different  CNT  lengths,  functionalization  degree 
and so on. Due to the fast clearance of amino-CNTs 
from blood, the in vivo applications of amino-CNTs 
still require more efforts to improve their pharmaco-
kinetics profile, though various demonstrations have 
been established at cellular level [44, 45]. However, 
the  amino-CNTs  showed  potential  in  delivering 
siRNA to tumor via intratumoral injection [46] and to 
brain via injection in the primary motor cortex [47]. 
For  future  studies,  prolonging  the  side  chains  of 
amino functional groups might be helpful to improve 
the pharmacokinetics. 
Other CNT samples tested show less potential in 
biomedical areas. We have studied the pharmacoki-
netics of hydroxylated SWCNTs (SWCNTols) [23, 48] 
and taurine functionalized MWCNTs (tau-MWCNTs) 
[18].  SWCNTols  distributed  rapidly  throughout  the 
whole  body  at  2  min  postexposure  to  mice  via  tail 
intravenous injection. The blood circulation  half-life 
of SWCNTols was around 10 min [48]. The migration 
of SWCNTols in body seemed nearly free, that was Theranostics 2012, 2(3) 
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also  evidenced  by  very  similar  distribution  profiles 
after  the  exposures  by  different  injection  methods 
[23]. The very short circulation time and free migra-
tion will limit the bio-applications of SWCNTols. On 
the other hand, tau-MWCNTs targeted liver quickly 
and stayed long there for months. The hepatic uptake 
of  tau-MWCNTs  was  higher  than  80%ID  (%  of  in-
jected dose) [18, 26], while the circulation half-life was 
around  12  min  [26].  The  short  circulation  time  and 
high RES uptake indicate the difficulty of the bioap-
plications  of  tau-MWCNTs.  Tyrosine  functionalized 
MWCNTs suffer the same problem as tau-MWCNTs 
do [49]. 
 
 
 
Figure  4.  Biodistribution  of  two  different  amino-SWCNTs  in 
mice  after  intravenous  injection.  Insets  show  the  schematic 
structures of amino-SWCNTs. Adapted from reference [41] with 
permission. 
 
 
As  discussed  above,  the  pharmacokinetics  of 
CNTs is very important for the biomedical applica-
tions.  There  are  many  parameters  regulating  the 
pharmacokinetics of CNTs, such as size, charge and 
surface  chemistry.  For  CNTs,  when  the  length  is 
smaller than 2 μm, CNTs can escape the pulmonary 
capillary vessels and their pharmacokinetics is mainly 
determined by the surface chemistry. Among the re-
ported surface chemistry, PEGylation is a most effi-
cient method in improving the pharmacokinetics pro-
file  of  CNTs.  The  development  of  easy,  cheap  and 
reproducible  PEGylation  techniques  becomes  a  cru-
cial route for the biomedical applications of CNTs. 
Metabolism and transformation of CNTs 
CNTs employed for biomedical purposes are in 
forms of either dispersed or functionalized ones. After 
introducing  to  biosystems,  it  is  possible  that  these 
CNTs  are  metabolized  into  other  substances.  The 
metabolism of CNTs definitely affects their biomedi-
cal  applications  and  also  might  lead  to  unwanted 
toxicity.  Therefore,  the  in vivo  metabolism  of  CNTs 
should be highly concerned. Unfortunately, the me-
tabolism  of  carbon  nanomaterials  is  very  hard  to 
study, because of the lack of proper analytical tech-
niques. Only few pilot studies are available in litera-
ture. 
The skeleton of CNTs is relatively more stable 
than  their  functional  groups.  We  have  shown  the 
transmission  electron  microscopy  (TEM)  images  of 
SWCNTs and MWCNTs (both pristine and function-
alized)  trapped  in vivo  for  more  than  4  weeks.  The 
trapped CNTs even stayed as long as 3 months [18, 
20]. The typical tube like or linear structure of CNTs 
was clearly recognized under TEM,  suggesting  that 
the carbon skeletons of CNTs were very stable against 
in  vivo  metabolism  as  well  as  the  subsequent  acid 
treatment for preparing the TEM samples. During the 
purification  and  shortening  processes,  CNTs  would 
go  through  strong  acid  (HNO3,  HCl  and  H2SO4) 
treatment,  sometimes  assisted  by  ultrasonication. 
Under  such  harsh  conditions,  the  carbon  skeleton 
only  breaks  at  the  injured  defects.  The  stability  of 
CNTs is also reflected by the long-term accumulation 
in vivo without being metabolized, where CNTs were 
visualized  in  mouse  organs  upon  TEM  at  several 
months postexposure [18, 20, 31]. Unlike most com-
mon results, Allen et al. observed the biodegradation 
of SWCNTs through enzymatic catalysis in vitro [50]. 
SWCNTs were incubated in PBS (pH 7.0) in presence 
of horseradish peroxidase and H2O2 in dark. After 16 
weeks  degradation,  the  loss  of  tube  structure  was 
identified  by  TEM,  thermogravimetric  analysis 
(TGA),  matrix-assisted  laser  desorption-ionization 
time-of-flight mass spectrometry  (MOLDI-TOF MS), 
dynamic light scattering (DLS), nanotube density of 
states band diagram and UV-vis-NIR spectra. For the Theranostics 2012, 2(3) 
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studies of biocompatibility and applications, the bio-
degradation of CNTs is an important factor to be re-
garded. Kagan et al. reported that the degradation by 
neutrophil myeloperoxidase reduced the pulmonary 
toxicity  of  CNTs  significantly  [51].  The  stability  of 
carbon skeleton also implies that CNTs are hard to be 
metabolized to small molecules, which may easily be 
excreted via urine and feces. More attention should be 
paid  to  design  proper  surface  property  of  CNTs  to 
accelerate the beneficial excretion of CNTs. 
 
 
 
Figure 5. TEM images of SWCNTs in digested solution of liver (a) 
and lungs (b) at 90 days postexposure. Adapted from reference 
[20] with permission. 
 
 
In contrast to the stability of carbon skeleton, the 
functional groups on CNTs are much easier to fall off 
from CNTs. There are two kinds of strategies to func-
tionalize  CNTs,  namely  chemical  functionalization 
and  dispersion  (non-covalent  functionalization). 
Current results suggest that both kinds of functional 
groups could be detached from CNTs in vivo and this 
makes  functionalized  CNTs  transformed  into  less 
functionalized or pristine CNTs. 
CNTs could be non-covalently functionalized by 
adsorbing reagents to their surface via hydrophobic 
interaction  and  π-π  interaction.  The  metabolism  of 
non-covalently  functionalized  CNTs  is  generally  re-
garded  as  desorption  of  the  suspending  reagents. 
Cherukuri et al. studied the replacement of adsorbed 
surfactants (Pluronic F108) on CNTs by serum pro-
teins  using  NIR  fluorescence  [25].  The  NIR  fluores-
cence  spectrum  of  SWCNTs  broadened  and 
red-shifted after the sample was introduced into the 
blood  circulation.  Such  phenomenon  was  also  ob-
served after adding the serum proteins. The positions 
and widths of SWCNT fluorescence peaks varied with 
the nature of the surrounding medium. Therefore, the 
serum proteins might replace Pluronic F108 molecules 
and stick to the surface of SWCNTs. The replacement 
of adsorbed surfactants by proteins seems to happen 
only at the high protein concentrations, because at the 
low  protein  concentrations,  surfactant  adsorption  is 
very stable against being replaced. Another interest-
ing  example  of  desorption  comes  from 
lysophophatidylcholine  (LPC)  coated  SWCNTs  [52]. 
Roberts et al. reported that LPC coated SWCNTs could 
be ingested by Daphnia magna. When food supply was 
stopped,  Daphnia  magna  would  take  LPC  from 
SWCNT surface as food source. After desorption of 
LPC,  the  naked  SWCNTs  aggregated  and  were  ex-
creted. In contrary to the results of  Cherukuri et al. 
and Roberts et al., Liu et al. found PEG-PL suspended 
SWCNTs, a novel platform for theranostics, were very 
stable.  The  hydrophobic  chains  of  PL  stuck  to  the 
SWCNT surface, while PEG chain stretched into the 
aqueous environment. The whole structure was simi-
lar to the micelle structure. The suspension was stable 
against salts, high temperature and also the biosys-
tems [24]. The PEG-PL suspended SWCNTs were ex-
creted  via  urine  and  feces  [31].  Comparing  to  the 
long-term accumulation of pristine SWCNTs, the slow 
excretion of PEG-PL/SWCNTs implies that such ma-
terials are stable in vivo (naked SWCNTs are hardly 
excreted).  The  inconsistency  in  literature  should  be 
attributed to the different CNT samples, suspending 
reagents,  and  biosystems.  In  particular,  SWCNTs 
used for the preparation of PEG-PL/SWCNTs were 
very short (~100 nm in length), so the slow excretion 
might be expected. For theranostics applications, sta-
ble suspended CNTs are more preferable. Thus, more 
efficient  and  stable  suspending  reagents,  such  as 
PEG-PL, are recommended. 
 
 
 
 
Figure 6. Replacement of Pluronic F108 on SWCNTs by serum 
proteins. The desorption is characterized by NIR fluorescence 
spectra. Adapted from reference [25] with permission. Theranostics 2012, 2(3) 
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Chemical modification is successfully used in the 
biomedical applications of CNTs. Various molecules, 
including  small  molecules,  polymers  and  biomole-
cules, have been covalently linked to the carbon skel-
eton of CNTs [2]. Generally, covalent bonds are more 
stable than non-covalent ones. Therefore, the stability 
of  covalently  functionalized  CNTs  is  expected.  We 
performed an in vivo evaluation of PEG-SWCNTs by 
using  Raman  spectroscopy  [53].  PEGylation  made 
SWCNTs  fluorescent,  and  the  Raman  signals  of 
SWCNTs  were  covered  by  the  strong  fluorescence. 
The recovered Raman signals were taken as the indi-
cator of metabolism, because the defunctionalization 
of PEG-SWCNTs in this case led to the depression of 
fluorescence and the recovery of Raman signal. After 
intravenous  injection  PEG-SWCNTs  accumulated  in 
liver and spleen for a long time. Due to the different 
functions of liver and spleen, PEG-SWCNTs showed 
different stabilities in these two organs. Liver is the 
most important metabolism organ, containing plenty 
of metabolic enzymes. PEG-SWCNTs trapped in liver 
defunctionalized  slowly  postexposure.  Obvious  Ra-
man signal recovery was observed at 4 weeks post-
exposure. The simulated experiments suggested that 
the hepatic defunctionalization of PEG-SWCNTs was 
resulted from both effects of radical attack and acid 
hydrolysis.  On  the  other  hand,  PEG-SWCNTs  were 
very  stable  against  biotransformation  in  spleen  for 
more  than  8  weeks.  Considering  that  spleen  is  the 
biggest  immunological  organ  and  plays  important 
roles  in  blood  purification,  the  stability  of 
PEG-SWCNTs in spleen is reasonable.  
 
 
Figure  7.  Defunctionalization  of  PEG-SWCNTs  in  liver  after 
intravenous injection reflected by Raman spectra (the inset fea-
turing the region around 1590 cm-1, from bottom up: the control, 
1 day, 1 week, and 4 weeks postexposure). Adapted from refer-
ence [53] with permission. 
Our results suggest that the metabolism of CNTs 
in vivo is organ-dependent, which requires individual 
evaluation for each accumulation organ. The hepatic 
defunctionalization  indicates  that  liver  is  the  most 
possible  metabolic  organ  in  body  for  CNTs.  Less 
functionalized  CNTs  are  believed  to  be  more  toxic. 
Therefore, the hepatic toxicity of CNTs  needs more 
attentions. 
Because of the high stability of carbon skeleton, 
the metabolism of CNTs mainly means defunctional-
ization of the surface functional groups. Comparing 
the  stability  of  non-covalently  and  covalently  func-
tionalized CNTs in vivo, the covalently functionalized 
CNTs  seem  more  stable  than  non-covalently  sus-
pended ones. This phenomenon indicates that cova-
lently modified CNTs are more suitable for biomedi-
cal  use  in  vivo  from  the  stability  view.  For  the 
non-covalently  suspended  CNTs,  using  more  stable 
suspending reagents, such as PEG-PL is preferred. 
Toxicity of CNTs in vivo 
The biosafety of CNTs is currently a most con-
cerned and discussed issue for their biomedical ap-
plications. The unique characteristics of CNTs make 
some traditional toxicological assays inapplicable. For 
example,  Worle-Knirsch  et  al.  reported  that  MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay gave false positive results in evaluat-
ing the cytotoxicity of CNTs [54]. Toxicity of CNTs 
remains in debate at cellular level, mainly due to the 
difference among the CNT samples. At in vivo level, 
more evaluations are made for the pulmonary toxicity 
of CNTs, regarding to the professional exposure. For 
biomedical  applications,  toxicological  information 
achieved  through  intravenous,  subcutaneous  and 
gastrointestinal exposure is more important. Current 
results conclude that CNTs are of low toxicity through 
the aforementioned pathways. 
CNTs show relative high biocompatibility post 
intravenous  injection.  Generally,  simply  dispersed 
CNTs  are  more  toxic  than  the  covalently  modified 
ones, but the toxicity of simply dispersed CNTs is still 
very  low,  even  with  a  long-term  observation.  We 
evaluated  the  long-term  toxicity  of  Tween  80  dis-
persed SWCNTs [20]. Serum biochemical index indi-
cated that SWCNTs induced damage to hepatic func-
tion.  The  dose-dependent  increases  of  alanine  ami-
notransferase  (ALT)  and  aspartate  aminotransferase 
(AST) levels reminded us that there was dose effect 
for the toxicity of SWCNTs. Histopathological anal-
yses showed that SWCNTs induced inflammation and 
inflammatory  cell  infiltration  in  lungs.  We  did  not 
find the changes of serum immunological levels and 
the increase of apoptosis. The toxicity of SWCNTs was Theranostics 2012, 2(3) 
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closely related to the oxidative stress. Lacerda  et al. 
reported that pristine MWCNTs dispersed by serum 
were  more  toxic  than  amino-MWCNTs  [27].  More 
weight loss and inflammation occurred in the pristine 
MWCNTs treated mice. 
 
 
 
Figure 8. Long-term toxicity of Tween 80 dispersed SWCNTs to 
mice after intravenous injection. (a) Serum biochemical index; (b, 
c) Histopathology of liver (b) and lungs (c). White arrows indicate 
the trapped SWCNTs. Adapted from reference [20] with per-
mission. 
 
 
Chemically  functionalized  CNTs  show  higher 
biocompatibility.  We  performed  the  first  toxicity 
evaluation  of  CNTs  after  intravenous  injection  [18]. 
The  serum  biochemical  index  and  histopathological 
characteristics of mice kept unchanged after exposure 
to  tau-MWCNTs.  We  concluded  that  tau-MWCNTs 
were  nearly  nontoxic.  Generally,  other  chemically 
functionalized CNTs are also of low toxicity. For ex-
ample, Deng et al. reported that oxidized MWCNTs 
(O-MWCNTs)  and  tau-MWCNTs  induced  low  tox-
icity to mice [55]. Only slight inflammatory response, 
mitochondria destruction and oxidative damage were 
observed  at  high  concentrations.  Qu  et al.  reported 
that  less  dispersed  O-MWCNTs  were  trapped  in 
lungs  and  induced  inflammation  there  [56]. 
O-MWCNTs  did  not  affect  the  hepatic  function. 
However, slight histopathological changes presented 
in  spleen  and  kidneys.  Repeated  administrations  of 
O-MWCNTs and MWCNTs-NH2 (O-MWCNTs linked 
with 1, 3-diaminopropane) to mice induced decreased 
germinative layer thickness and vacuolization of Ser-
toli cells [57]. The testis damage was reversible and 
the fertility was not affected at all. Other indicators, 
such  as  oxidative  stress,  bodyweight,  organ  index, 
sperm  concentration,  motility,  morphology  and 
acrosome integrity, kept at the normal levels just as 
the  control  group.  Amino-MWCNTs  also  showed 
very good biocompatibility [27]. They did not accu-
mulate long in body, and the toxicological indicators 
(histopathology,  serum  biochemistry,  hematology 
and urinalysis) remained normal. It seems that well 
functionalization improves the dispersibility of CNTs, 
avoids the filtration of CNTs by pulmonary capillary 
vessels and reduces the toxicity consequently. 
Again, PEGylated CNTs exhibit very good bio-
compatibility.  Schipper  et  al.  reported  that 
PEG-SWCNTs and PEG-PL/SWCNTs were nontoxic 
and biocompatible [22]. Although both SWCNTs re-
tained in liver for more than 4 months, mice exposed 
to  PEG-SWCNTs  and  PEG-PL/SWCNTs  behaved 
normally. There was no statistical difference of body 
weight increase and blood pressure between the ex-
posed and the control groups. The hematological and 
serum biochemical indicators also suggested that both 
samples  were  nontoxic.  Slightly  higher  toxicity  of 
PEG-MWCNTs  (covalently  PEGylated  MWCNTs) 
was  detected  and reported  by  Zhang  et al.  [58].  In-
flammatory infiltration and low-grade spotty necrosis 
presented in histopathological analyses. The damage 
to  mitochondria,  such  as  mitochondrial  destruction 
and lysis of mitochondrial crest, were observed under 
TEM.  Inflammatory  gene  expression  was 
up-regulated,  but  tumor  necrosis  factor-α  (TNF-α) 
level remained unchanged. The hepatic function was 
not affected according to serum biochemical indica-
tors.  No  oxidative  damage  was  detected,  because 
glutathione (GSH) and superoxide dismutase (SOD) 
remained  normal  levels.  It  is  worth  to  note  that 
PEG-MWCNTs  only  showed  toxicity  at  very  high 
dosage (60 mg/kg). At lower dosages, PEG-MWCNTs 
were  nearly  nontoxic.  The  nontoxic  nature  of 
PEGylated CNTs at low dosages is a very good prop-
erty  for  biomedical  applications.  Considering  that 
there  might  be  metabolism  (defunctionalization)  in 
vivo,  the  fate  and  consequence  of  PEGylated  CNTs 
should be carefully studied in future. 
CNTs exposed by oral gavage are of low toxicity, 
too. Folkmann et al. reported that SWCNTs induced 
oxidative damages to DNA after oral gavage [59]. The 
indicator,  premutagenic  8-oxo-7,8-dihydro-2’- 
deoxyguanosine  (8-oxodG),  only  increased  in  liver Theranostics 2012, 2(3) 
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and lungs. SWCNTs suspended in corn oil induced 
more  DNA  damages  than  these  in  PBS.  Yang  et al. 
observed the oxidative damage in mice induced by 
SWCNTs via oral gavage [60]. SWCNTs were found in 
liver and intestine. SWCNTs targeted lysosome and 
mitochondria,  and  then  induced  collapse  of  mito-
chondrial membrane potentials, generating more re-
active  oxygen  species  leading  to  the  mitochondrial 
damage. 
CNTs can be used as tissue engineering materi-
als for cell growth. After implanting subcutaneously, 
CNTs exhibited very good biocompatibility. Bellucci 
et al. reported that implanted MWCNT paper did not 
arouse  any  serious  toxicity,  except  very  limited  in-
flammation [61]. Fraczek et al. found that implanted 
SWCNTs and MWCNTs induced inflammation [62]. 
Smaller SWCNT aggregates migrated to lymph nodes 
nearby. Other reports on the toxicity of CNTs to skin 
suggested  that  CNTs  were  biocompatible  to  skin, 
which was consistent with the good biocompatibility 
after subcutaneously planting. 
 
 
Figure 9. Hematological indicators of mice exposed to PEG-SWCNTs and PEG-PL/SWCNTs. MCV: mean corpuscular volume; MCH: 
mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration. Adapted from reference [22] with permission. 
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Figure 10. Muscle implanted with CNTs after 7 and 90 days of implantation. No uniform fibrous capsule separates the implant from the 
muscle tissue. Adapted from reference [62] with permission. 
 
 
As discussed above, there are several parameters 
affecting the toxicity of CNTs in vivo. Oxidative stress 
is observed in despite of the administration pathways. 
Metal  impurities  might  contribute  partially  to  the 
oxidative stress, thus, careful purification of CNTs is 
necessary. In fact, the surface chemical functionaliza-
tion is also a purification process for CNTs. Among 
these functionalization methods, PEGylation is highly 
recommended. A possible hypothesis is that PEGyla-
tion prevents proteins adsorb onto CNTs, hence re-
duces the interaction between CNTs and biosystem. 
In  addition  to  surface  chemistry,  other  parameters 
might also influence the toxicity of CNTs. Shape is an 
important factor influencing the toxicity of CNTs. In 
literature,  the  fiber-like  CNTs  (longer)  were  more 
toxic than the rod-like CNTs (shorter) [63]. Size is an-
other important influencing factor. Bigger aggregates 
of CNTs accumulate in lungs and induce the pulmo-
nary  toxicity,  while  smaller  ones  hardly  affect  the 
pulmonary functions [20, 27]. 
The  available  safety  data  collectively  indicate 
that  CNTs  are  of  low  toxicity  via  various  exposure 
pathways for biomedical applications. CNTs induce 
meaningful toxicity only when a very high dosage is 
administrated. Thus, we come to a verdict that CNTs 
are  generally  biocompatible  and  low  toxic  for  the 
biomedical  purposes.  More  toxicity  evaluations  are 
encouraged to give the safety threshold value (dosage 
limit) of different CNTs and clarify the toxicological 
mechanism. Carefully optimizing the physicochemi-
cal  parameters  to  minimize  the  toxicity  of  CNTs  is 
highly favorable. 
Conclusions 
In summary, we summarized the updated data 
of CNTs from the biomedical view with focus on the 
pharmacokinetics, metabolism and toxicity of CNTs in 
vivo.  The  connection  between  the  pharmacological 
applications  and  toxicological  information  of  CNTs 
was  discussed.  The  pharmacokinetics,  metabolism 
and toxicity of CNTs are dependent on the physico-
chemical parameters  of CNTs and regulated by  the 
surface chemistry. Well functionalized CNTs by both 
non-covalent and covalent methods are promising for 
the  biomedical  applications.  PEGylation  is  a  most 
efficient method to improve the in vivo behaviors of 
CNTs. In future studies, systematic evaluation of the 
long-term toxicity of CNT exposure is worthy of spe-
cial attention. Moreover, establishing fast and reliable 
analytical techniques for in vivo behavior evaluation 
should  always  be  concerned,  particularly,  for  the 
newly developed nanomaterials. Theranostics 2012, 2(3) 
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